var data={"title":"Vitamin B3 (niacin): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vitamin B3 (niacin): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6646?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vitamin-b3-niacin-drug-information\" class=\"drug drug_general\">see &quot;Vitamin B3 (niacin): Drug information&quot;</a> and <a href=\"topic.htm?path=vitamin-b3-niacin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vitamin B3 (niacin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200983\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Niacin-50 [OTC];</li>\n      <li>Niacor;</li>\n      <li>Niaspan;</li>\n      <li>Slo-Niacin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200984\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Niaspan;</li>\n      <li>Niaspan FCT;</li>\n      <li>Niodan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054368\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antilipemic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Water Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443901\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">Adequate intake: 2 mg/day (IOM 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054361\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vitamin-b3-niacin-drug-information\" class=\"drug drug_general\">see &quot;Vitamin B3 (niacin): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Formulations of niacin (regular release [crystalline] versus extended release) are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake </b>(IOM 1998)<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 5 months: 2 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to 11 months: 3 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowances </b>(IOM 1998)<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: 6 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: 8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 13 years: 12 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">14 to 18 years: Female: 14 mg/day; Male: 16 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dyslipidemias: </b>Very limited data available (Miller 2015): <b>Note:</b> Niacin (nicotinic acid) is rarely used in pediatric patients for treatment of dyslipidemias and is not considered a primary agent nor a routine secondary, adjunctive agent for dyslipidemia management in pediatric patients (AAP [Daniels 2008]; AHA [McCrindle 2007]; NHLBI 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;10 years and Adolescents (Miller 2015; NHLBI 2011): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Regular release: Initial: 100 to 250 mg/day in 3 divided doses with meals; maximum initial daily dose: 10 mg/kg/<b>day</b>; increase weekly by 100 mg/day or increase every 2 to 3 weeks by 250 mg/day as tolerated; evaluate efficacy and adverse effects with laboratory tests at 20 mg/kg/day or 1,000 mg/day (whichever is less); continue to increase if needed and as tolerated; re-evaluate at each 500 mg increment; daily doses up to 2,250 mg/<b>day</b> have been used (Colletti 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sustained release: Reported range: 500 to 1,500 mg/day; initiate at a low dose administered once daily (based on experience in adults); reported initial daily dose has not exceeded 10 mg/kg/<b>day;</b> titrate every 3 to 4 weeks (in adults, doses are titrated every 4 weeks) (AHA [McCrindle 2007]; Colletti 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pellagra; treatment</b>: Children and Adolescents: Oral: Regular release: 50 to 300 mg/day in divided doses 3 times daily; usual treatment duration is 3 to 4 weeks (Kliegman 2016; WHO 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dietary supplement</b>: Oral: 50 mg twice daily or 100 mg once daily. <b>Note:</b> Many over-the-counter formulations exist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dyslipidemia:</b> <b>Note:</b> Niacin is no longer recommended, except in specific clinical situations (eg, high triglyceride levels [&gt;500 mg/dL], if not able to achieve desired response, or intolerance to other therapies) (ACC 2016; Boden 2014; Garg 2017; Landray 2014; Wierzbicki 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Regular release formulation (Niacor): Initial: 250 mg once daily (with evening meal); increase frequency and/or dose every 4 to 7 days to desired response or first-level therapeutic dose (1.5 to 2 g/day in 2 to 3 divided doses); after 2 months, may increase at 2- to 4-week intervals to 3 g/day in 3 divided doses (maximum dose: 6 g/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained release (or controlled release) formulations: <b>Note:</b> Several over-the-counter formulations exist. Slo-Niacin: Usual dosage is 250 to 750 mg once daily, taken morning or evening, or as directed. Before using more than 500 mg daily, patient should consult health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release formulation (Niaspan): Initial: 500 mg at bedtime for 4 weeks, then 1 g at bedtime for 4 weeks; adjust dose to response and tolerance; may increase dose every 4 weeks by 500 mg/day to a maximum of 2 g/<b>day</b>. Recommended maintenance dose: 1 to 2 g at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Contraindicated in patients with significant or unexplained hepatic dysfunction, active liver disease, or unexplained persistent transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b>Children and Adolescents: In a trial of pediatric patients, discontinuation of niacin therapy was reported for hepatotoxicity (eg, transaminases increases, either persistent or if symptoms of nausea, fever, and/or malaise), headache, abdominal pain and/or severe flushing (Colletti 1993)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200962\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (100 g, 1000 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niacin-50: 50 mg [starch free, sugar free, wheat free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niacor: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg, 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg [DSC], 100 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niaspan: 500 mg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niaspan: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niaspan: 750 mg, 1000 mg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Slo-Niacin: 250 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Slo-Niacin: 500 mg, 750 mg [scored; contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 750 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200948\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054372\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with food or milk to decrease GI upset; to minimize flushing: Administer dose at bedtime; premedicate with aspirin (adults: 325 mg) 30 minutes before niacin; and avoid alcohol, hot drinks, or spicy food around the time of administration. In adults, may also use other NSAIDs to prevent flushing according to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niaspan: Administer at bedtime with a low-fat snack (do not administer on an empty stomach). Two of the 500 mg and one of the 1,000 mg tablet strengths are interchangeable, but three of the 500 mg and two of the 750 mg tablet strengths are not interchangeable. When switching from immediate-release tablet, initiate Niaspan with the recommended titration schedule. If therapy is interrupted for an extended period, dose should be retitrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Long-acting forms should not be crushed, broken, or chewed. Slo-Niacin may be broken along the score line. Do not substitute long-acting forms for regular/immediate release preparations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5943168\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054371\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regular release: Dietary supplement (OTC: FDA approved in adults); has also been used for the management of dyslipidemia and treatment of pellagra</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sustained/controlled or extended release: Treatment of dyslipidemias (Fredrickson types IIa and IIb or primary hypercholesterolemia) as mono- or adjunctive therapy; to lower the risk of recurrent MI in patients with a history of MI and hyperlipidemia; to slow progression or promote regression of coronary artery disease; adjunctive therapy for severe hypertriglyceridemia in patients at risk of pancreatitis (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Niacin (nicotinic acid) is rarely used in pediatric patients for treatment of dyslipidemias and is not considered a primary agent nor a routine secondary, adjunctive agent for dyslipidemia management in pediatric patients (AAP [Daniels 2008]; AHA [McCrindle 2007]; NHLBI 2011). Although niacin consistently affects surrogate markers in adults, especially LDL-C, it has not been shown to reduce cardiovascular disease outcomes beyond that achieved with statin use and may be associated with harm (ACC 2016; Garg 2017; Wierzbicki 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201016\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Niacin may be confused with Minocin, niacinamide, Niaspan </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201014\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, cardiac arrhythmia, edema, flushing, hypotension, orthostatic hypotension, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, headache, insomnia, migraine, myasthenia, nervousness, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acanthosis nigricans, burning sensation of skin, diaphoresis, hyperpigmentation, maculopapular rash, pruritus, skin discoloration, skin rash, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased glucose tolerance, decreased serum phosphate, gout, hyperuricemia, increased amylase, increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, eructation, flatulence, nausea, peptic ulcer, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased platelet count, prolonged prothrombin time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis, increased serum bilirubin, increased serum transaminases (dose-related), jaundice,</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, leg cramps, myalgia, myopathy (with concurrent HMG-CoA reductase inhibitor), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, cystoid macular edema, toxic amblyopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatic necrosis, hypersensitivity reaction (includes anaphylaxis, angioedema, laryngismus, vesiculobullous rash), rhabdomyolysis (with concurrent HMG-CoA reductase inhibitor), syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200968\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to niacin, niacinamide, or any component of the formulation; active hepatic disease or significant or unexplained persistent elevations in hepatic transaminases; active peptic ulcer; arterial hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200952\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flushing/pruritus: Flushing and pruritus are common adverse effects of niacin; may be attenuated with a gradual increase in dose, administering with food, avoidance of concurrent ingestion of ethanol, hot or spicy foods/liquids, and/or by taking aspirin 30 minutes before dosing. May also use other NSAIDs according to the manufacturer. Flushing associated with extended-release preparation is significantly reduced (Guyton 2007). For immediate-release preparations, may administer in 2 to 3 divided doses to reduce the frequency and severity of flushing/pruritus. Consider discontinuation if persistent severe cutaneous symptoms occur during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: May cause GI distress, vomiting, diarrhea, or aggravate peptic ulcer; GI distress may be attenuated with a gradual increase in dose and administration with food. Use is contraindicated in patients with active peptic ulcer disease; use with caution in patients with a past history of peptic ulcer. Consider discontinuation if unexplained abdominal pain/weight loss or other GI symptoms occur during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Dose-related reductions in platelet count and increases of prothrombin time may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred when immediate-release (crystalline) niacin products have been substituted with sustained-release (modified-release, timed-release) niacin products at equivalent doses. Patients should be initiated with low doses (eg, niacin extended-release 500 mg at bedtime) with titration to achieve desired response. Liver function tests should be monitored in all patients receiving lipid-lowering doses of niacin. Discontinue use if hepatic transaminase levels rise, particularly to 3 x ULN and are persistent, or if they are associated with symptoms of nausea, fever, and/or malaise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypophosphatemia: Has been associated with small but statistically significant dose-related reductions in phosphorus levels. Monitor phosphorus levels periodically in patients at risk for hypophosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with unstable angina or in the acute phase of an MI. In patients with preexisting coronary artery disease, the incidence of atrial fibrillation was observed more frequently in those receiving immediate-release (crystalline) niacin as compared to placebo (Coronary Drug Project Research Group 1975). Consider discontinuation if new-onset atrial fibrillation occurs during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use is associated with new-onset diabetes or worsening glucose tolerance in patients with preexisting diabetes (Garg 2017; Goldie 2016). Use with caution in patients with diabetes. Monitor glucose; adjustment of diet and/or hypoglycemic therapy may be necessary. Consider discontinuation if persistent hyperglycemia occurs during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: May be associated with hyperuricemia. Use with caution in patients predisposed to gout. Consider discontinuation if acute gout occurs during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with a past history of hepatic impairment; monitor liver function tests. Contraindicated with active liver disease or unexplained persistent transaminase elevation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Formulations of niacin (immediate-release versus extended-release) are not interchangeable (bioavailability varies): cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred in patients who have substituted niacin products at equivalent doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol use: Use with caution in patients who consume large amounts of ethanol due to the increased risk of liver dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50978666\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, a high incidence of reversible adverse effects has been observed; in a dyslipidemia trial (n=21, age range: 4 to 14 years), flushing was most common (71%); increased liver enzymes were observed in 29% of patients; in the trial, dosage form (crystalline or sustained release) did not affect adverse effect incidence (Colletti 1993).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299759\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2914257\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12642&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Niacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Niacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Niacin may enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Niacin may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Niacin may increase the serum concentration of Simvastatin.  Management: Use of simvastatin 80 mg with niacin should be avoided and simvastatin doses over 20 mg/day should be used cautiously in Chinese patients; some non-US labeling state this combination is not recommended in any Asian patients.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200958\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5943163\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Water soluble vitamins cross the placenta. When used as a dietary supplement, niacin requirements may be increased in pregnant women compared to nonpregnant women (IOM 1998). It is not known if niacin at lipid-lowering doses is harmful to the developing fetus. If a woman becomes pregnant while receiving niacin for primary hypercholesterolemia, niacin should be discontinued. If a woman becomes pregnant while receiving niacin for hypertriglyceridemia, the benefits and risks of continuing niacin should be assessed on an individual basis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054367\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests pretreatment, every 6 to 12 weeks for first year, then periodically (approximately every 6 months), monitor liver function more frequently if history of transaminase elevation with prior use; lipid profile. Blood glucose (in diabetic patients); if on concurrent HMG-CoA reductase inhibitor, may periodically check CPK and serum potassium; platelets (if on anticoagulants); PT (if on anticoagulants); uric acid (if predisposed to gout); phosphorus (if predisposed to hypophosphatemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200951\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Niacin (nicotinic acid) is bioconverted to nicotinamide which is further converted to nicotinamide adenine dinucleotide (NAD+) and the hydride equivalent (NADH) which are coenzymes necessary for tissue metabolism, lipid metabolism, and glycogenolysis (Belenky 2006; Sauve 2008). The mechanism by which niacin (in lipid-lowering doses) affects plasma lipoproteins is not fully understood. It may involve several actions including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity, which may increase the rate of chylomicron triglyceride removal from plasma. Ultimately, niacin reduces total cholesterol, apolipoprotein (apo) B, triglycerides, VLDL, LDL, lipoprotein (a), and increases HDL and other important components and subfractions (eg, LPA-I) (Kamanna 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200967\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Immediate release formulation: Rapid and extensive. Extent of niacin ER absorption from niacin ER/lovastatin is increased (22% to 30%) with food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;20% bound to serum proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive first-pass metabolism; converted to nicotinamide adenine dinucleotide, nicotinuric acid (after conjugation with glycine), and other metabolites. At doses used to treat hyperlipidemia, metabolic pathways are saturable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Single dose studies indicate that only certain Niaspan tablet strengths are interchangeable (ie, two 500 mg tablets are equivalent to one 1,000 mg tablet; however, three 500 mg tablets are <b>not</b> equivalent to two 750 mg tablets) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 20 to 48 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release formulation: 30 to 60 minutes; extended release formulation: 4 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine 60% to 88% (unchanged drug [up to 12% recovered after multiple dosing] and metabolites) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200970\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Niacin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $11.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Niacin ER (Antihyperlipidemic) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (90): $381.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (90): $543.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $674.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Niacin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $4.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $6.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $7.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (100): $8.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Niaspan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (90): $558.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (90): $796.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (90): $987.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Slo-Niacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $9.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1000): $139.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (100): $18.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Niacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $1.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $3.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $4.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Niacor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $354.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200972\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acido Nicotinico (CO);</li>\n      <li>Acidum nicotinicum (HU);</li>\n      <li>Apo-Nicotinic Acid (NZ);</li>\n      <li>Exlip ER (KR);</li>\n      <li>Niacyn (PL);</li>\n      <li>Niapid (BD);</li>\n      <li>Niaspan (BB, CH, DE, FI, GB, HK, NL, PT, SE, TH);</li>\n      <li>Niaspan LP (FR);</li>\n      <li>Niaspanor (KR);</li>\n      <li>Nicangin (NO);</li>\n      <li>Nicobid (HK);</li>\n      <li>Nicoson (BD);</li>\n      <li>Nicotabs (TH);</li>\n      <li>Nicotinic Acid (AU);</li>\n      <li>Nyclin (TW);</li>\n      <li>Pepevit (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;ASHP Therapeutic Position Statement on the Safe Use of Niacin in the Management of Dyslipidemias. American Society of Health-System Pharmacists,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(24):2815-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/9428952/pubmed\" target=\"_blank\" id=\"9428952\">9428952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. <i>Trends Biochem Sci</i>. 2006;32(1):12-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/17161604/pubmed\" target=\"_blank\" id=\"17161604\">17161604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24363242\"></a>Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. <i>J Cardiovasc Pharmacol Ther</i>. 2014;19(2):141-158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/24363242/pubmed\" target=\"_blank\" id=\"24363242\">24363242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colletti RB, Neufeld EJ, Roff NK, et al, &ldquo;Niacin Treatment of Hypercholesterolemia in Children.&rdquo; <i>Pediatrics</i>, 1993, 92(1):78-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/8516088/pubmed\" target=\"_blank\" id=\"8516088\">8516088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The Coronary Drug Project Research Group, &ldquo;Clofibrate and Niacin in Coronary Heart Disease,&rdquo; <i>JAMA</i>, 1975, 231(4):360-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/1088963/pubmed\" target=\"_blank\" id=\"1088963\">1088963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daniels SR, Greer FR, and American Academy of Pediatrics Committee on Nutrition, &quot;Lipid Screening and Cardiovascular Health in Childhood,&quot; <i>Pediatrics</i>, 2008, 122(1):198-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/18596007/pubmed\" target=\"_blank\" id=\"18596007\">18596007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1998. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27793642\"></a>Garg A, Sharma A, Krishnamoorthy P, et al. Role of niacin in current clinical practice: a systematic review. <i>Am J Med</i>. 2017;130(2):173-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/27793642/pubmed\" target=\"_blank\" id=\"27793642\">27793642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldie C, Taylor AJ, Nguyen P, et al. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. <i>Heart</i>. 2016;102(3):198-203. doi: 10.1136/heartjnl-2015-308055.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/26370223/pubmed\" target=\"_blank\" id=\"26370223\">26370223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyton JR, Bays HE. Safety considerations with niacin therapy. <i>Am J Cardiol</i>. 2007;99(6A):22C-31C.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/17368274/pubmed\" target=\"_blank\" id=\"17368274\">17368274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegyi J, Schwartz RA, and Hegyi V, &ldquo;Pellagra: Dermatitis, Dementia, and Diarrhea,&rdquo; <i>Int J Dermatol</i>, 2004, 43(1):1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/14693013/pubmed\" target=\"_blank\" id=\"14693013\">14693013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25014686\"></a>HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. <i>N Engl J Med</i>. 2014;371(3):203-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/25014686/pubmed\" target=\"_blank\" id=\"25014686\">25014686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B</i><sub>6</sub><i>, Folate, Vitamin B</i><sub>12</sub><i>, Pantothenic Acid, Biotin and Choline</i>, Washington, DC: National Academy Press, 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamanna VS, Kashyap ML. Mechanism of Action of Niacin on Lipoprotein Metabolism. <i>Curr Atheroscler Rep</i>. 2000;2(1):36-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/11122723/pubmed\" target=\"_blank\" id=\"11122723\">11122723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Urbina EM, Dennison BA, et al, &quot;Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2007, 115(14):1948-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/17377073/pubmed\" target=\"_blank\" id=\"17377073\">17377073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26343214\"></a>Miller ML, Wright CC, Browne B. Lipid-lowering medications for children and adolescents. <i>J Clin Lipidol</i>. 2015;9(5 Suppl):S67-S76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/26343214/pubmed\" target=\"_blank\" id=\"26343214\">26343214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NHLBI. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Published October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niaspan (niacin) extended-release tablet [prescribing information]. North Chicago, IL: AbbVie Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuna AA, &ldquo;Safe Use of Niacin,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(24):2803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/9428949/pubmed\" target=\"_blank\" id=\"9428949\">9428949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. <i>JPET</i>. 2008;324(3):883-893.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/18165311/pubmed\" target=\"_blank\" id=\"18165311\">18165311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25318657\"></a>Wierzbicki AS, Viljoen A. Fibrates and niacin: is there a place for them in clinical practice? <i>Expert Opin Pharmacother</i>. 2014;15(18):2673-2680.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/25318657/pubmed\" target=\"_blank\" id=\"25318657\">25318657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Pellagra and its prevention and control in major emergencies. Available at http://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/. Published 2000.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27046161\"></a>Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2016;68(1):92-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vitamin-b3-niacin-pediatric-drug-information/abstract-text/27046161/pubmed\" target=\"_blank\" id=\"27046161\">27046161</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12642 Version 159.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F200983\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F200984\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054368\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443901\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054361\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200962\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F200948\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054372\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F5943168\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054371\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201016\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201014\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200968\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200952\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50978666\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299759\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2914257\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F200958\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5943163\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054367\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200951\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F200967\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F200970\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F200972\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12642|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vitamin-b3-niacin-drug-information\" class=\"drug drug_general\">Vitamin B3 (niacin): Drug information</a></li><li><a href=\"topic.htm?path=vitamin-b3-niacin-patient-drug-information\" class=\"drug drug_patient\">Vitamin B3 (niacin): Patient drug information</a></li></ul></div></div>","javascript":null}